logo
logo
Sign in

Influenza Diagnostics Market Report 2023 | Coronavirus-COVID19 Impact Analysis

avatar
Vinit Sawant

Influenza as an illness can cause severe complications and mess up anybody's medical history. Influenza is of various types and with a variety of deadly symptoms. Hence, early diagnosis of influenza can reduce the chances of further complications. Therefore, with World Health Organization (WHO) confirming about 600 million Influenza cases worldwide, the services offering accurate Influenza diagnosis are going to be in-demand always and become a part of a huge market in the medical sector.

Market Research Future (MRFR) has published a report about the global influenza diagnostics market. This report expects 5.8% CAGR during the forecast period between 2017 and 2023. In terms of cash, this market is expected to grow with US $ 700.7 mn by 2023.

The three forms of type A are bird flu, seasonal flu, and Swine flu. On the basis of direct fluorescent antibody (DFA) tests, molecular tests, nucleic acid sequence-based amplification (NASBA) tests, rapid influenza detection tests (RIDT), serological assays, simple amplification-based assays (SAMBA) and loop-mediated isothermal amplification-based assays (LAMP). Serological assays are segmented into primary serological tests, secondary serological tests, and tertiary serological tests. Primary serological tests cover enzyme-linked immunosorbent assay (ELISA), immunofluorescent antibody technique (IFAT) and radioimmunoassay (RIA). Secondary Serological tests include agglutination tests, complement fixation tests (CFT), precipitation tests, serum neutralization tests (SNT) and toxin-antitoxin test.

Key Players

The key players in global influenza diagnostics market include Alere (USA), BD (USA), Becton Dickinson (USA), BioMérieux SA (France), Cepheid (USA), Hardy Diagnostics(USA), LifeSign LLC.(USA), Meridian Bioscience, Inc.(USA), Quidel Corporation (USA), Roche Molecular Systems Inc.(Switzerland), and Sekisui Diagnostics (USA).

Latest Industry News

  • Medical technology company Becton Dickinson (BD), currently a key player in global influenza diagnostics market, has formally opened a new research facility at Plassey Technological Park in Limerick. This business expansion has created 85 new jobs at its Irish operations. Currently, BD employs more than 1,300 employees in Ireland across Drogheda, Dun Laoghaire and its two sites in Limerick.

 

 

collect
0
avatar
Vinit Sawant
guide
Zupyak is the world’s largest content marketing community, with over 400 000 members and 3 million articles. Explore and get your content discovered.
Read more